Overview: Current status of clinical trials
- 15 May 1990
- Vol. 65 (S10), 2371-2375
- https://doi.org/10.1002/1097-0142(19900515)65:10+<2371::aid-cncr2820651503>3.0.co;2-s
Abstract
The five areas outlined in this discussion represent a large proportion of the current environment for clinical trials. They identify significant obstacles to the advancement of knowledge in clinical oncology. There is no single or overriding solution to the health care system and its problems with funding and access or to the antiintellectual mood of our times. Continuous efforts to improve science are needed now more than ever. Adequate accession to trials is an ongoing issue. These problems are compounded by the ethical issues created by today's opportunities. The etiquette of territoriality is no less daunting. Each of these affects the environment in which trials are conducted, and each deserves the serious attention of all of us. Some suggestions for action have been made. The need for resolution is obvious.Keywords
This publication has 9 references indexed in Scilit:
- Health Care Rationing through InconvenienceNew England Journal of Medicine, 1989
- Adjuvant Therapy for Node-Negative Breast CancerNew England Journal of Medicine, 1989
- NIH Grapples with Conflict of InterestScience, 1989
- Prolonged Disease-Free Survival after One Course of Perioperative Adjuvant Chemotherapy for Node-Negative Breast CancerNew England Journal of Medicine, 1989
- Efficacy of Adjuvant Chemotherapy in High-Risk Node-Negative Breast CancerNew England Journal of Medicine, 1989
- A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive TumorsNew England Journal of Medicine, 1989
- A Randomized Clinical Trial Evaluating Sequential Methotrexate and Fluorouracil in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor-Negative TumorsNew England Journal of Medicine, 1989
- The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1988
- Prolongation of the Disease-Free Interval in Surgically Treated Rectal CarcinomaNew England Journal of Medicine, 1985